Its Gene Therapy Roctavian Finally Approved With $2.9m Price, BioMarin Aims To Prove Doubters Wrong

FDA Label Muddies Efficacy Claims

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.